2023
Animal models of Huntington’s disease and their applicability to novel drug discovery and development
Upadhayay S, Jamwal S, Kumar P. Animal models of Huntington’s disease and their applicability to novel drug discovery and development. Expert Opinion On Drug Discovery 2023, 18: 527-538. PMID: 37042034, DOI: 10.1080/17460441.2023.2201493.Peer-Reviewed Original ResearchConceptsHD animal modelsAnimal modelsHuntington's diseaseNon-motor symptomsProgressive neurodegenerative disorderDrug therapyDisease progressionPreclinical phaseLoss of functionNeurodegenerative disordersClinical phaseDrug discoveryDiseaseNovel drug discoveryHuntingtin geneToxic gainCAG trinucleotide repeatDrugsProgressionHD geneEnormous progressionAn Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Upadhayay S, Yedke N, Rahi V, Singh S, Kumar S, Arora A, Chandolia P, Kaur P, Kumar M, Koshal P, Jamwal S, Kumar P. An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. Neurochemical Research 2023, 48: 1631-1647. PMID: 36738367, DOI: 10.1007/s11064-023-03868-1.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsDisease Models, AnimalDrug DiscoveryHuntington DiseaseNeurotoxinsNitro CompoundsPropionatesConceptsMedium spiny neuronsAnimal modelsGABAergic medium spiny neuronsDisease modelsKey clinical manifestationsHuntington's disease modelsPathogenesis of diseaseWeb of ScienceClinical manifestationsPathophysiological mechanismsSpiny neuronsPreclinical studiesMotor impairmentLike symptomsTherapeutic targetExperimental animalsExcessive productionHuntington's diseaseOxidative stressDiseasePathogenic conditionsDrug discoveryMitochondrial functionFree radicalsNeurotoxin
2020
Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives
Jamwal S, Elsworth JD, Rahi V, Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Review Of Neurotherapeutics 2020, 20: 1123-1141. PMID: 32720531, DOI: 10.1080/14737175.2020.1801424.Peer-Reviewed Original ResearchConceptsGene therapyClinical trialsDisease-modifying therapiesMutant huntingtinTreatment of HDAntibody-based therapiesPotential therapeutic interventionsNew therapeutic targetsGene-based therapiesImmune activationClinical dataImmunotherapyTherapeutic targetFunctional restorationTherapeutic interventionsTherapyHD pathogenesisMHTT proteinRecent updatesFuture perspectivesPromising strategyTrialsCurrent statusConsiderable attentionHD
2019
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Jamwal S, Kumar P. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review. Current Neuropharmacology 2019, 17: 165-175. PMID: 29512464, PMCID: PMC6343208, DOI: 10.2174/1570159x16666180302115032.Peer-Reviewed Original ResearchConceptsParkinson's diseaseHuntington's diseaseStriatal neurotransmittersNeuronal deathNeurotransmitter levelsAltered neurotransmitters levelBasal ganglia regionsExcitotoxic neuronal deathNeurotransmitter alterationsBrain dopaminePathophysiological basisBasal gangliaGanglia regionsMovement disordersPreclinical studiesReceptor densitySpecific drugsCoordinated body movementsDiseaseNeurotransmittersAltered levelsOxidative stressExact mechanismMitochondrial dysfunctionImportant neurotransmitter
2016
Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington’s like symptoms in rats: Possible neurotransmitters modulation
Gill JS, Jamwal S, Kumar P, Deshmukh R. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington’s like symptoms in rats: Possible neurotransmitters modulation. Pharmacological Reports 2016, 69: 306-313. PMID: 28178592, DOI: 10.1016/j.pharep.2016.11.008.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCorpus StriatumDisease Models, AnimalGamma-Aminobutyric AcidGlutamic AcidHuntington DiseaseInterleukin-1betaInterleukin-6Lipid PeroxidationMaleMotor ActivityNeuroprotective AgentsNeurotransmitter AgentsOxidative StressQuinolinic AcidRatsRats, WistarRotarod Performance TestSertralineTumor Necrosis Factor-alphaVenlafaxine HydrochlorideConceptsMotor performanceQuinolinic acidAvailable drugsPro-inflammatory cytokine levelsNumerous neuroprotective propertiesAnti-inflammatory propertiesGrip strength testProgressive neurodegenerative disorderBDNF levelsCytokine levelsSymptomatic reliefNeuroprotective effectsRotarod testMonoamine levelsNeuroprotective propertiesStriatal atrophyNeurobehavioral deficitsNeurotransmitter levelsNeurotransmitter modulationGlutamatergic signalingRat striatumNeurochemical analysisBody weightDay 22Neurochemical levelsL-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway
Jamwal S, Kumar P. L-theanine, a Component of Green Tea Prevents 3-Nitropropionic Acid (3-NP)-Induced Striatal Toxicity by Modulating Nitric Oxide Pathway. Molecular Neurobiology 2016, 54: 2327-2337. PMID: 26957301, DOI: 10.1007/s12035-016-9822-5.Peer-Reviewed Original ResearchConceptsHuntington's diseaseStriatal toxicityL-NAMENeuroprotective potentialConcurrent treatmentProtective effectBody weightL-arginineL-theanineGABAergic medium spiny neuronsGreen tea preventsStriatal neurotransmitter levelsPro-inflammatory mediatorsPro-inflammatory cytokinesNitric oxide pathwayBlood-brain barrierMedium spiny neuronsNitric oxide productionL-theanine treatmentNeurotransmitter alterationsOxide pathwayBrain barrierSpiny neuronsNeurotransmitter levelsRat striatum
2015
Antidepressants for neuroprotection in Huntington's disease: A review
Jamwal S, Kumar P. Antidepressants for neuroprotection in Huntington's disease: A review. European Journal Of Pharmacology 2015, 769: 33-42. PMID: 26511378, DOI: 10.1016/j.ejphar.2015.10.033.Peer-Reviewed Original ResearchConceptsHuntingtin proteinHuntington's diseaseMAPK/ERK signalingBrain-derived neurotrophic factor (BDNF) productionBDNF/TrkB pathwayProgression of HDDifferent neuroprotective mechanismsPrincipal neuropathological hallmarksUse of antidepressantsNeurotrophic factor productionCortical projection neuronsMutant huntingtin proteinCellular functionsPolyglutamine stretchMolecular mechanismsNH2 terminusERK signalingTrkB pathwayPreclinical evidenceNeuroprotective effectsNeuroprotective mechanismsCommon symptomsProjection neuronsAvailable treatmentsDisease progressionProtective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism
Jamwal S, Singh S, Kaur N, Kumar P. Protective Effect of Spermidine Against Excitotoxic Neuronal Death Induced by Quinolinic Acid in Rats: Possible Neurotransmitters and Neuroinflammatory Mechanism. Neurotoxicity Research 2015, 28: 171-184. PMID: 26078029, DOI: 10.1007/s12640-015-9535-y.Peer-Reviewed Original ResearchConceptsQuinolinic acidBody weightQA treatmentGABAergic medium spiny neuronsN-methyl-D-aspartate receptorsOxidative stressGABAergic neuronal lossPro-inflammatory levelsHyperkinetic movement disordersExcitotoxic cell deathAnti-inflammatory propertiesExcitotoxic neuronal deathMedium spiny neuronsReceptor antagonistic propertiesNeuroinflammatory mechanismsPossible neurotransmittersNeuroinflammatory markersNeuronal lossNeuroprotective effectsNeurotransmitter alterationsCatecholamine levelsCascade of eventsNeuronal deathSpiny neuronsMovement disorders